BUSINESSglobal
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Single source
Updated 3 hours ago
First seen March 18, 2026 22:54:41Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.